Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2012

Open Access 01-12-2012 | Research

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer

Authors: Alan Katz, Montserrat Ferrer, José Francisco Suárez, Multicentric Spanish Group of Clinically Localized Prostate Cancer

Published in: Radiation Oncology | Issue 1/2012

Login to get access

Abstract

Background

As the long-term efficacy of stereotactic body radiation therapy (SBRT) becomes established and other prostate cancer treatment approaches are refined and improved, examination of quality of life (QOL) following prostate cancer treatment is critical in driving both patient and clinical treatment decisions. We present the first study to compare QOL after SBRT and radical prostatectomy, with QOL assessed at approximately the same times pre- and post-treatment and using the same validated QOL instrument.

Methods

Patients with clinically localized prostate cancer were treated with either radical prostatectomy (n = 123 Spanish patients) or SBRT (n = 216 American patients). QOL was assessed using the Expanded Prostate Cancer Index Composite (EPIC) grouped into urinary, sexual, and bowel domains. For comparison purposes, SBRT EPIC data at baseline, 3 weeks, 5, 11, 24, and 36 months were compared to surgery data at baseline, 1, 6, 12, 24, and 36 months. Differences in patient characteristics between the two groups were assessed using Chi-squared tests for categorical variables and t-tests for continuous variables. Generalized estimating equation (GEE) models were constructed for each EPIC scale to account for correlation among repeated measures and used to assess the effect of treatment on QOL.

Results

The largest differences in QOL occurred in the first 1–6 months after treatment, with larger declines following surgery in urinary and sexual QOL as compared to SBRT, and a larger decline in bowel QOL following SBRT as compared to surgery. Long-term urinary and sexual QOL declines remained clinically significantly lower for surgery patients but not for SBRT patients.

Conclusions

Overall, these results may have implications for patient and physician clinical decision making which are often influenced by QOL. These differences in sexual, urinary and bowel QOL should be closely considered in selecting the right treatment, especially in evaluating the value of non-invasive treatments, such as SBRT.
Appendix
Available only for authorised users
Literature
1.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998, 280: 969-974. 10.1001/jama.280.11.969CrossRefPubMed
2.
Klein EA: Radiation therapy versus radical prostatectomy in the PSA era: a urologist’s view. Semin Radiat Oncol 1998, 8: 87-94. 10.1016/S1053-4296(98)80004-0CrossRefPubMed
3.
4.
Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM: Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009, 8: 387-392.CrossRefPubMed
5.
Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M: Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10: 1. 10.1186/1471-2490-10-1PubMedCentralCrossRefPubMed
6.
King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009, 73: 1043-1048. 10.1016/j.ijrobp.2008.05.059CrossRefPubMed
7.
Klotz L: Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Urol Rep 2012, 13: 153-159. 10.1007/s11934-012-0242-4CrossRefPubMed
8.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al.: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367: 203-213. 10.1056/NEJMoa1113162PubMedCentralCrossRefPubMed
9.
Ferrer M, Suarez JF, Guedea F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, et al.: Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72: 421-432. 10.1016/j.ijrobp.2007.12.024CrossRefPubMed
10.
Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL: Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 2004, 101: 2011-2019. 10.1002/cncr.20608CrossRefPubMed
11.
Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, Schroder FH, de Koning HJ: Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005, 116: 291-296. 10.1002/ijc.21043CrossRefPubMed
12.
Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE: Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007, 109: 2239-2247. 10.1002/cncr.22676CrossRefPubMed
13.
Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004, 96: 1358-1367. 10.1093/jnci/djh259CrossRefPubMed
14.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al.: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358: 1250-1261. 10.1056/NEJMoa074311CrossRefPubMed
15.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56: 899-905. 10.1016/S0090-4295(00)00858-XCrossRefPubMed
16.
Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J, et al.: Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010, 28: 4687-4696. 10.1200/JCO.2009.25.3245CrossRefPubMed
17.
18.
Athanassiou H, Antonadou D, Coliarakis N, Kouveli A, Synodinou M, Paraskevaidis M, Sarris G, Georgakopoulos GR, Panousaki K, Karageorgis P, Throuvalas N: Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003, 56: 1154-1160. 10.1016/S0360-3016(03)00187-1CrossRefPubMed
19.
Simone NL, Menard C, Soule BP, Albert PS, Guion P, Smith S, Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, et al.: Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by EPIC score. Int J Radiat Oncol Biol Phys 2008, 70: 90-95. 10.1016/j.ijrobp.2007.05.057PubMedCentralCrossRefPubMed
20.
Ferrer M, Garin O, Pera J, Prats JM, Mendivil J, Alonso J, De Paula B, Herruzo I, Hervas A, Macias V, et al.: Evaluation of the quality of life of patients with localizad prostate cancer: validation of the Spanish version of the EPIC. Med Clin (Barc) 2009, 132: 128-135. 10.1016/j.medcli.2008.01.001CrossRef
21.
Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41: 582-592.PubMed
22.
Twisk J, de Vente W: Attrition in longitudinal studies. How to deal with missing data. J Clin Epidemiol 2002, 55: 329-337. 10.1016/S0895-4356(01)00476-0CrossRefPubMed
23.
Lepor H, Kaci L, Xue X: Continence following radical retropubic prostatectomy using self-reporting instruments. J Urol 2004, 171: 1212-1215. 10.1097/01.ju.0000110631.81774.9cCrossRefPubMed
24.
Nandipati KC, Raina R, Agarwal A, Zippe CD: Nerve-sparing surgery significantly affects long-term continence after radical prostatectomy. Urology 2007, 70: 1127-1130. 10.1016/j.urology.2007.07.042CrossRefPubMed
25.
Donnellan SM, Duncan HJ, MacGregor RJ, Russell JM: Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis. Urology 1997, 49: 225-230. 10.1016/S0090-4295(96)00451-7CrossRefPubMed
26.
Smith JA Jr, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS: A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol 2007, 178: 2385-2389. discussion 2389–2390 10.1016/j.juro.2007.08.008CrossRefPubMed
27.
Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR: Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012, 82: 228-234. 10.1016/j.ijrobp.2010.10.026CrossRefPubMed
28.
King CR, Brooks JD, Gill H, Presti JC Jr: Long-term outcomes from a prospective trial of stereotactic body radiotherapy for Low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82: 887-882.
29.
McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, Collins SP, Kaplan ID: Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2011,118(15):3681-3690.CrossRefPubMed
30.
Patel VR, Coelho RF, Chauhan S, Orvieto MA, Palmer KJ, Rocco B, Sivaraman A, Coughlin G: Continence, potency and oncological outcomes after robotic-assisted radical prostatectomy: early trifecta results of a high-volume surgeon. BJU Int 2010, 106: 696-702. 10.1111/j.1464-410X.2010.09541.xCrossRefPubMed
31.
Brandina R, Berger A, Kamoi K, Gill IS: Critical appraisal of robotic-assisted radical prostatectomy. Curr Opin Urol 2009, 19: 290-296. 10.1097/MOU.0b013e328329a356CrossRefPubMed
32.
Hakimi AA, Blitstein J, Feder M, Shapiro E, Ghavamian R: Direct comparison of surgical and functional outcomes of robotic-assisted versus pure laparoscopic radical prostatectomy: single-surgeon experience. Urology 2009, 73: 119-123. 10.1016/j.urology.2008.08.491CrossRefPubMed
33.
Singh I, Hemal AK: Robotic-assisted radical prostatectomy in 2010. Expert Rev Anticancer Ther 2010, 10: 671-682. 10.1586/era.10.35CrossRefPubMed
34.
Rocco B, Matei DV, Melegari S, Ospina JC, Mazzoleni F, Errico G, Mastropasqua M, Santoro L, Detti S, de Cobelli O: Robotic vs open prostatectomy in a laparoscopically naive centre: a matched-pair analysis. BJU Int 2009, 104: 991-995. 10.1111/j.1464-410X.2009.08532.xCrossRefPubMed
35.
Finkelstein J, Eckersberger E, Sadri H, Taneja SS, Lepor H, Djavan B: Open versus laparoscopic versus robot-assisted laparoscopic prostatectomy: the European and US experience. Rev Urol 2010, 12: 35-43.PubMedCentralPubMed
36.
Levinson AW, Lavery HJ, Ward NT, Su LM, Pavlovich CP: Is a return to baseline sexual function possible? An analysis of sexual function outcomes following laparoscopic radical prostatectomy. World J Urol 2011, 29: 29-34. 10.1007/s00345-010-0616-5CrossRefPubMed
37.
Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM: Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int 2012, 109: 898-905. 10.1111/j.1464-410X.2011.10551.xCrossRefPubMed
38.
Wiegner EA, King CR: Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010, 78: 442-448. 10.1016/j.ijrobp.2009.07.1748CrossRefPubMed
39.
Echner GG, Kilby W, Lee M, Earnst E, Sayeh S, Schlaefer A, Rhein B, Dooley JR, Lang C, Blanck O, et al.: The design, physical properties and clinical utility of an iris collimator for robotic radiosurgery. Phys Med Biol 2009, 54: 5359-5380. 10.1088/0031-9155/54/18/001CrossRefPubMed
40.
Poll JJ, Hoogeman MS, Prevost JB, Nuyttens JJ, Levendag PC, Heijmen BJ: Reducing monitor units for robotic radiosurgery by optimized use of multiple collimators. Med Phys 2008, 35: 2294-2299. 10.1118/1.2919090CrossRefPubMed
41.
Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R: Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010, 9: 473-477.CrossRefPubMed
42.
Ham WS, Kim SW, Kim WT, Park SY, Choi YD: Robotic prostatectomy in patient with an abdominoperineal resection. J Laparoendosc Adv Surg Tech A 2009, 19: 383-387. 10.1089/lap.2008.0110CrossRefPubMed
43.
Murphy DG, Kerger M, Crowe H, Peters JS, Costello AJ: Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. Eur Urol 2009, 55: 1358-1366. 10.1016/j.eururo.2008.12.035CrossRefPubMed
44.
Boike TP, Lotan Y, Cho LC, Brindle J, Derose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, et al.: Phase I dose-escalation study of stereotactic body radiation therapy for Low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29: 2020-2026. 10.1200/JCO.2010.31.4377PubMedCentralCrossRefPubMed
45.
Kang JK, Cho CK, Choi CW, Yoo S, Kim MS, Yang K, Yoo H, Kim JH, Seo YS, Lee DH, Jo M: Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011, 97: 43-48.PubMed
46.
Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67: 1099-1105. 10.1016/j.ijrobp.2006.10.050CrossRefPubMed
Metadata
Title
Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
Authors
Alan Katz
Montserrat Ferrer
José Francisco Suárez
Multicentric Spanish Group of Clinically Localized Prostate Cancer
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2012
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-7-194

Other articles of this Issue 1/2012

Radiation Oncology 1/2012 Go to the issue

Research

Amelioration of radiation-induced skin injury by adenovirus-mediated heme oxygenase-1 (HO-1) overexpression in rats

Research

Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index

Research

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Research

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan

Research

Evaluation of heterogeneity dose distributions for Stereotactic Radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms

Research

Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients